Hemangioma, Capillary: Clinical Trials

63 trials for Hemangioma, Capillary, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 completed, 9 terminated, 8 recruiting, 6 unknown. 18 Phase 2, 14 Not applicable, 7 Phase 3, 4 Phase 4, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 218Completed 8, Terminated 4, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1, Withdrawn 1
Not applicable14Completed 9, Recruiting 3, Not yet recruiting 1, Suspended 1
Phase 37Completed 4, Recruiting 1, Terminated 1, Unknown 1
Phase 44Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Phase 13Completed 2, Terminated 1
Early Phase 12Terminated 2

Follow Hemangioma, Capillary: new trials by email Literature Review of Hemangioma, Capillary trials Research Report on Hemangioma, Capillary

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
Rapamycin cream, Pulsed dyed laser - Port Wine Stains
Phase 2Not yet recruitingAFT Pharmaceuticals, Ltd.302026-11-132026-10-27
Preoperative Embolization for Highly Vascular Brain Tumors
Preoperative Endovascular Embolization - Brain Neoplasms, Meningioma
Not applicableNot yet recruitingAssiut University552026-10-012026-09-17
Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients
Pulse Dye laser, Pulse Dye Laser (PDL) pulse width stacking, Pulse Dye Laser (PDL) followed by Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet laser) laser. - Port Wine Stains
Not applicableRecruitingUniversity of Texas Southwestern Medical Center2002026-07-012026-06-05
Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma
Abrupt Discontinuation of Propranolol, Gradual Tapering of Propranolol - Infantile Hemangioma (IH)
Phase 4Not yet recruitingWest China Hospital1102026-07-012026-06-24
Risk Stratification and Treatment Decisions in Infantile Hemangioma With Minimal or Arrested Growth
Routine Clinical Assessment and Risk Stratification - Infantile Hemangioma (IH)
Not yet recruitingWest China Hospital1502026-06-202026-07-02
Screening LUMBAR Syndrome in Infants With Infantile Hemangiomas
MRI - LUMBAR Syndrome
Not yet recruitingWest China Hospital702026-06-012026-06-01
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
propranolol - Infantile Hemangioma
Phase 2 / Phase 3RecruitingWest China Hospital322025-01-012026-09-21
Oral Propranolol Versus Fractional Carbon Dioxide CO2 Laser Assisted Delivery of Topical Timolol for Treatment of Infantile Hemangioma
Propranolol 1, Fractional CO2 laser with topical timolol - Infantile Hemangioma (IH)
Not applicableCompletedCairo University302025-01-012026-05-01
Exploration and Evaluation of Amygdalo-Hippocampectomy According to Prof. Coubes' Technique: An Anatomical, Clinical, and Educational Approach
Amygdalo-Hippocampectomy - Hippocampal Sclerosis, Dysembryoplastic Neuroepithelial Tumor
RecruitingUniversity Hospital, Montpellier35042024-08-312025-04-08
Agnostic Therapy in Rare Solid Tumors
Nivolumab - Urachal Cancer, Parathyroid Carcinoma
Phase 2Active not recruitingInstituto do Cancer do Estado de São Paulo282024-07-162026-10-13
Enhanced Efficacy Through Optimization of Hemoporfin-Photodynamic Therapy Parameters in Port-Wine Stains
irradiation at 84 mW/cm² for 17 minutes per spot, irradiation at 75 mW/cm² for 19 minutes per spot - Port Wine Stains
Not applicableCompletedSecond Affiliated Hospital of Xi'an Jiaotong University332024-07-012026-01-20
Low-Dose Propranolol and Bleomycin for Infantile Hemangioma (IH)
Propranolol + Bleomycin, Propranolol - Infantile Hemangioma (IH)
Not applicableCompletedWuhan Integrated Traditional Chinese and Western Medicine Hospital2602024-01-012025-08-05
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Belzutifan - Von Hippel Lindau, Von Hippel Lindau Disease
Phase 2RecruitingJosé Claudio Casali da Rocha1002024-01-012025-09-11
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Observational - Glioma, Glioneuronal Tumor
RecruitingEuropean Organisation for Research and Treatment of Cancer - EORTC16502023-03-212025-12-17
Propranolol and Von Hippel-Lindau Disease
Propranolol, follow-up - Hemangioblastoma of CNS, Von Hippel-Lindau Disease
Not applicableRecruitingAssistance Publique - Hôpitaux de Paris852023-01-162023-12-13
Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations
Functional navigation - Tumor, Brain, Arteriovenous Malformations
Not applicableSuspendedSklifosovsky Institute of Emergency Care502022-09-012025-05-16
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
Propranolol three times a day, Propranolol twice a day, Timolol - Infantile Hemangioma
Phase 4TerminatedThe University of Texas Health Science Center, Houston522022-06-232026-03-13
Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution
Hemangioma, Capillary
CompletedCentral Hospital, Nancy, France2242021-03-232021-10-18
Efficacy of Intralesional Bleomycin Alone and in Combination With Dexamethasone in Infantile Haemangiomas
Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone - Comparison of Efficacy of Sclerotherapy in Infantile Hemangioma
Not applicableCompletedKing Edward Medical University1142021-03-222023-10-12
''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
Propranolol Therapy for Infantile Hemangioma - Infantile Hemangioma
Phase 2UnknownAssiut University1002021-01-012020-12-24

Showing 20 of 63. Sign in to see all of them.

Narrower conditions

Hemangioblastoma (16)  ·  Hemangioma (13)  ·  von Hippel-Lindau Disease (10)  ·  Vascular Malformations (4)  ·  Brain Neoplasms (3)  ·  Carcinoma, Renal Cell (3)  ·  Central Nervous System Neoplasms (3)  ·  Meningioma (3)  ·  Neoplasms (3)  ·  Cholangiocarcinoma (2)  ·  Cysts (2)  ·  Hemangioma, Cavernous (2)  ·  Neuroectodermal Tumors, Primitive (2)  ·  Paraganglioma (2)

Broader conditions

Neoplasms by Histologic Type (63)  ·  Neoplasms, Vascular Tissue (63)  ·  Neoplasms (60)  ·  Hemangioma (50)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (21)  ·  Nervous System Diseases (20)  ·  Congenital Abnormalities (19)  ·  Cardiovascular Diseases (18)  ·  Vascular Diseases (14)  ·  Genetic Diseases, Inborn (12)  ·  Neoplasms by Site (12)  ·  Neurocutaneous Syndromes (11)  ·  Abnormalities, Multiple (10)  ·  Angiomatosis (10)

Interventions

Propranolol (8)  ·  Timolol (7)  ·  Lasers, Dye (3)  ·  Atenolol (2)  ·  Imiquimod (2)  ·  Nadolol (2)  ·  Population Groups (2)  ·  Sunitinib (2)  ·  4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1)  ·  Adrenergic beta-Antagonists (1)  ·  Alfentanil (1)  ·  Amikacin (1)  ·  Aminocaproic Acid (1)  ·  Bevacizumab (1)  ·  Bleomycin (1)

Sponsors

West China Hospital (6)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (3)  ·  Assiut University (2)  ·  M.D. Anderson Cancer Center (2)  ·  Pierre Fabre Dermatology (2)  ·  The Hospital for Sick Children (2)  ·  University Hospital, Montpellier (2)  ·  University of California, Irvine (2)  ·  AFT Pharmaceuticals, Ltd. (1)  ·  Ain Shams University (1)  ·  Alice K. Gong (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Auson Pharmaceuticals Inc. (1)  ·  Bispebjerg Hospital (1)

Countries

United States (28)  ·  China (12)  ·  France (9)  ·  Canada (5)  ·  Spain (4)  ·  Egypt (3)  ·  Brazil (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Russia (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Austria (1)

Top investigators

Eric Jonasch, MD (2)  ·  Prashant Chittiboina, M.D. (2)  ·  Adrienne Hammill, MD, PhD (1)  ·  Albert C. Yan, MD (1)  ·  Alexander Dmitriev, MD (1)  ·  Alfons L. Krol, M.D. (1)  ·  Alice K Gong, M.D. (1)  ·  Alice K Gong, MD (1)  ·  Beth Drolet, MD (1)  ·  Camila MV Moniz, Doctor (1)  ·  Catherine McCuaig, M.D. (1)  ·  Chi Hornik, PharmD (1)  ·  Christine Labreze, MD (1)

Results publications

PMID 19419474, PMID 20598318, PMID 20828712, PMID 22105611, PMID 23301692, PMID 24579662, PMID 24614374, PMID 24949994, PMID 25693013, PMID 26039810, PMID 26813215, PMID 26926644, PMID 27062495, PMID 27522443, PMID 28137820, PMID 28290120, PMID 28779462, PMID 29084742, PMID 29271816, PMID 29435949, PMID 29571951, PMID 29677389, PMID 30584062, PMID 30790601, PMID 31317556, PMID 31548185, PMID 31814149, PMID 32324313, PMID 32497307, PMID 33029806, PMID 33118199, PMID 33856430, PMID 33903114, PMID 34302290, PMID 34747977, PMID 34783716, PMID 35275019, PMID 35370711, PMID 35491971, PMID 35661809, PMID 35751738, PMID 37018064, PMID 37333396, PMID 38134265, PMID 38134268, PMID 38553990, PMID 38759778, PMID 39612031, PMID 40327835, PMID 40614265

NIH funding

2008 (1), 2025 (1), U01NS104157 (1)